Targeted therapy plus chemotherapy for her2-positive advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs (against HER2) plus a chemotherapy drug called irinotecan for people with HER2-positive colorectal cancer that has spread and has not responded to standard treatments. The goal is to see if this combo can shrink or control the cancer better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your colorectal cancer has spread to other parts of the body (metastatic).
- Your tumor is HER2-positive (a specific protein found on some cancer cells).
- Your tumor does not have KRAS, NRAS, or BRAF mutations.
- You have tried at least one chemotherapy that included a drug called irinotecan, and your cancer kept growing.
- You are generally feeling well (able to do daily activities) and your blood tests are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two targeted drugs (trastuzumab and pertuzumab biosimilars) plus chemotherapy can shrink advanced HER2-positive rectal cancer before surgery. It aims to improve response and potentially reduce the need for more aggressive treatments.
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
This trial tests a new drug combination for people with advanced colorectal cancer that has a specific protein called HER2. The treatment includes a targeted drug (trastuzumab rezetecan) plus chemotherapy and another targeted drug (bevacizumab) to see if it can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (trastuzumab deruxtecan, capecitabine, and bevacizumab) as the first treatment for people with HER2-positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Hear when a new HER2 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.